Tissue Kallikrein 1 (KLK1) Therapeutics Market : Global Industry Analysis and Opportunity Assessment, 2036

Future Market Insights

Tissue Kallikrein 1 (KLK1) Therapeutics Market

Key Insight

Recombinant KLK1 accounts for 56.1% of the tissue kallikrein 1 (KLK1) therapeutics market by product type. Preeclampsia leads the indication category with 40.4%, while vasodilation and endothelial function holds 64.4% of the mechanism segment.

July 30, 2026

Anurag Sharma

250 Pages

Cite this Report

Tissue Kallikrein 1 (KLK1) Therapeutics Market

https://www.futuremarketinsights.com/reports/tissue-kallikrein-1-klk1-therapeutics-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

DiaMedica Therapeutics
Catalent Pharma Solutions
Guangdong Techpool Bio-Pharma
Sanwa Kagaku Kenkyusho
Nichi-Iko Pharmaceutical
Unipharm Korea
Dongsung Bio Pharm
Dae Hwa Pharmaceutical

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Tissue Kallikrein 1 (KLK1) Therapeutics Market

Key Players

Similar Industry Reports